Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

Benjamin P. Sablan, Dong Joon Kim, Nina G. Barzaga, Wan Cheng Chow, Mong Cho, SangHoon Ahn, Seong Gyu Hwang, Ji Hyun Lee, Hamid Namini, William L. Heyward

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Adults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor 9 agonist, 1018 immunostimulatory sequence (1018 ISS) adjuvant, combined with recombinant hepatitis B surface antigen (HBsAg) demonstrated faster, superior, and more durable seroprotection than three doses of a licensed comparator HBV vaccine (Engerix-B®). This investigational vaccine, HBsAg-1018 ISS, was well tolerated with a safety profile similar to the comparator vaccine. These results suggest that HBsAg-1018 may be more effective in this hypo-responsive population.

Original languageEnglish
Pages (from-to)2689-2696
Number of pages8
JournalVaccine
Volume30
Issue number16
DOIs
Publication statusPublished - 2012 Mar 30

Fingerprint

Hepatitis B Vaccines
hepatitis B
Hepatitis B Surface Antigens
Hepatitis B
Vaccines
vaccines
Safety
Hepatitis B virus
Toll-Like Receptor 9
dosage
agonists
adjuvants
Population
hepatitis B antigens

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Sablan, Benjamin P. ; Kim, Dong Joon ; Barzaga, Nina G. ; Chow, Wan Cheng ; Cho, Mong ; Ahn, SangHoon ; Hwang, Seong Gyu ; Lee, Ji Hyun ; Namini, Hamid ; Heyward, William L. / Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. In: Vaccine. 2012 ; Vol. 30, No. 16. pp. 2689-2696.
@article{7753d5af86844e45a02dea95ed8f2f20,
title = "Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine",
abstract = "Adults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor 9 agonist, 1018 immunostimulatory sequence (1018 ISS) adjuvant, combined with recombinant hepatitis B surface antigen (HBsAg) demonstrated faster, superior, and more durable seroprotection than three doses of a licensed comparator HBV vaccine (Engerix-B{\circledR}). This investigational vaccine, HBsAg-1018 ISS, was well tolerated with a safety profile similar to the comparator vaccine. These results suggest that HBsAg-1018 may be more effective in this hypo-responsive population.",
author = "Sablan, {Benjamin P.} and Kim, {Dong Joon} and Barzaga, {Nina G.} and Chow, {Wan Cheng} and Mong Cho and SangHoon Ahn and Hwang, {Seong Gyu} and Lee, {Ji Hyun} and Hamid Namini and Heyward, {William L.}",
year = "2012",
month = "3",
day = "30",
doi = "10.1016/j.vaccine.2012.02.001",
language = "English",
volume = "30",
pages = "2689--2696",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "16",

}

Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. / Sablan, Benjamin P.; Kim, Dong Joon; Barzaga, Nina G.; Chow, Wan Cheng; Cho, Mong; Ahn, SangHoon; Hwang, Seong Gyu; Lee, Ji Hyun; Namini, Hamid; Heyward, William L.

In: Vaccine, Vol. 30, No. 16, 30.03.2012, p. 2689-2696.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

AU - Sablan, Benjamin P.

AU - Kim, Dong Joon

AU - Barzaga, Nina G.

AU - Chow, Wan Cheng

AU - Cho, Mong

AU - Ahn, SangHoon

AU - Hwang, Seong Gyu

AU - Lee, Ji Hyun

AU - Namini, Hamid

AU - Heyward, William L.

PY - 2012/3/30

Y1 - 2012/3/30

N2 - Adults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor 9 agonist, 1018 immunostimulatory sequence (1018 ISS) adjuvant, combined with recombinant hepatitis B surface antigen (HBsAg) demonstrated faster, superior, and more durable seroprotection than three doses of a licensed comparator HBV vaccine (Engerix-B®). This investigational vaccine, HBsAg-1018 ISS, was well tolerated with a safety profile similar to the comparator vaccine. These results suggest that HBsAg-1018 may be more effective in this hypo-responsive population.

AB - Adults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor 9 agonist, 1018 immunostimulatory sequence (1018 ISS) adjuvant, combined with recombinant hepatitis B surface antigen (HBsAg) demonstrated faster, superior, and more durable seroprotection than three doses of a licensed comparator HBV vaccine (Engerix-B®). This investigational vaccine, HBsAg-1018 ISS, was well tolerated with a safety profile similar to the comparator vaccine. These results suggest that HBsAg-1018 may be more effective in this hypo-responsive population.

UR - http://www.scopus.com/inward/record.url?scp=84862785552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862785552&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.02.001

DO - 10.1016/j.vaccine.2012.02.001

M3 - Article

VL - 30

SP - 2689

EP - 2696

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 16

ER -